Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

GeneQuantum Partners with Aimed Bio to Develop ADC for Brain Cancer

publication date: Apr 19, 2022

GeneQuantum Healthcare of Suzhou will co-develop a first-in-class therapeutic antibody drug conjugate (ADC) with Aimed Bio, a spin-off from Korea’s Samsung Medical Center. Aimed Bio develops innovative antibody-centric drugs for brain diseases that have few treatment options. GeneQuantum will apply its Ligase Dependent Conjugation (LDC) technology platform to the Aimed antibody, facilitating a site-specific conjugation of cytotoxins or other payload type. The company says its technology improves key therapeutic characteristics of existing molecules and creates new classes of molecules, expanding treatment options for patients. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital